RxDoctor Payments Data

Emily Martin, NP

Nurse Practitioner · Carbondale, ILNPI 1306504790

Payments from drug & device makers

$3,323in general payments, 2019–2025

Across 139 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$389
  • Regeneron Healthcare Solutions, Inc.$364
  • Sanofi$358
  • Mylan Specialty L.p.$162
  • Insmed, Inc.$143
  • plus $831 from 14 others

What the payments were for

  • Food & beverage$3,26598%
  • Education$572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,323 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$38,042
Medicare patients
183
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$60,403
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr69$35,793
DuleraMometasone/Formoterol62$22,739
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$18,245
Spiriva RespimatTiotropium Bromide30$16,957
Breo ElliptaFluticasone/Vilanterol29$13,249
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$5,962
Roflumilast55$5,435
Albuterol Sulfate HfaAlbuterol Sulfate136$3,383
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,970
Ventolin HfaAlbuterol Sulfate16$1,421
Montelukast Sodium34$316
Fluticasone Propionate25$230
Azithromycin11$69
Prednisone20$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$389$109,446180 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$75$22,91943 claims
MerckDulera$41$22,73962 claims
AstraZenecaBreztri Aerosphere$1,075$18,24530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →